MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma [PDF]
, 2018 Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient ...
Carnero Moya, Amancio +5 more
core +1 more source
miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. [PDF]
, 2015 MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC).
Cao, Yan +12 more
core +1 more source
Nature Communications, 2018 Amongst the non-small cell lung cancers, to date, lung squamous cell carcinoma remains the most challenging to treat. Here the authors report BCL11A as an important factor which together with SOX2 can drive lung squamous cell carcinoma development and ...
Kyren A. Lazarus +19 more
doaj +1 more source
Long non-coding RNA SOX2OT: Expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis [PDF]
, 2015 SOX2 overlapping transcript (SOX2OT) is a long non-coding RNA which harbors one of the major regulators of pluripotency, SOX2 gene, in its intronic region.
Jazi, M.S. +3 more
core +1 more source
Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging. [PDF]
, 2018 The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of human tumor and normal tissue ...
Adams, Julia +13 more
core +2 more sources
Frontiers in OncologyCombined Small Cell Lung Cancer (C-SCLC) is defined by the World Health Organization (WHO) as a combination of Small Cell Lung Cancer (SCLC) and other components, which may include any type of Non-Small Cell Lung Cancer (NSCLC).
Jishen Zhang +3 more
doaj +1 more source
Clinicopathological and Immunohistochemical Analysis of Lung Cancer Biopsies at a Tertiary Care Centre in Central Gujarat, India [PDF]
National Journal of Laboratory MedicineIntroduction: Lung biopsy is a reliable and highly accurate tool for diagnosing and subtyping lung lesions. Two-thirds of lung cancer patients present with advanced disease, and small biopsies remain the main diagnostic tool.
Yogita Vrajlal Kareliya +5 more
doaj +1 more source
EPMA position paper in cancer:current overview and future perspectives [PDF]
, 2015 At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare.
Bubnov, Rostylav +7 more
core +5 more sources
Changes on Mitochondrial DNA Content in Non-small Cell Lung Cancer [PDF]
, 2011 Background and objective It has been proven that the mitochondrial DNA (mtDNA) mutations and content change were associated with increasing risk of tumorigenesis. MtDNA content is significantly reduced in most substantive tumors. The aim of this study is
Hongmei WANG, Jigang DAI
core
Exploiting metabolic vulnerabilities of Non small cell lung carcinoma
Seminars in Cell & Developmental Biology, 2020 Lung cancer is the main cause of cancer death worldwide. Non-Small Cell Lung Carcinoma (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stages is still very poor. Given the need for new therapies, the metabolism of NSCLC has been widely studied in the past two decades to identify vulnerabilities that ...
Majem, Blanca +2 more
openaire +3 more sources